IL293133A - Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies - Google Patents

Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies

Info

Publication number
IL293133A
IL293133A IL293133A IL29313322A IL293133A IL 293133 A IL293133 A IL 293133A IL 293133 A IL293133 A IL 293133A IL 29313322 A IL29313322 A IL 29313322A IL 293133 A IL293133 A IL 293133A
Authority
IL
Israel
Prior art keywords
ccr9
disease
tnfa
blocking antibody
inhibitor
Prior art date
Application number
IL293133A
Other languages
English (en)
Hebrew (he)
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,861 external-priority patent/US10792360B1/en
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of IL293133A publication Critical patent/IL293133A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL293133A 2019-11-21 2020-11-20 Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies IL293133A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962938795P 2019-11-21 2019-11-21
US16/740,861 US10792360B1 (en) 2019-11-21 2020-01-13 Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
US17/064,550 US20210154292A1 (en) 2019-11-21 2020-10-06 Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
PCT/US2020/061569 WO2021102302A1 (en) 2019-11-21 2020-11-20 Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies

Publications (1)

Publication Number Publication Date
IL293133A true IL293133A (en) 2022-07-01

Family

ID=75974977

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293133A IL293133A (en) 2019-11-21 2020-11-20 Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies

Country Status (11)

Country Link
US (1) US20210154292A1 (https=)
EP (1) EP4061365A4 (https=)
JP (1) JP2023502267A (https=)
KR (1) KR20220103980A (https=)
CN (1) CN115209896A (https=)
AU (1) AU2020386066A1 (https=)
BR (1) BR112022009638A2 (https=)
CA (1) CA3159127A1 (https=)
IL (1) IL293133A (https=)
MX (1) MX2022006071A (https=)
WO (1) WO2021102302A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI904146B (zh) 2020-03-31 2025-11-11 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法
CN116492341B (zh) * 2023-05-19 2025-04-15 广州市红十字会医院 维塞诺在制备治疗白癜风药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566263A (en) * 2002-05-24 2009-09-25 Millennium Pharm Inc CCR9 inhibitors and methods of use thereof
WO2014088113A1 (en) * 2012-12-04 2014-06-12 Millennium Pharmaceuticals, Inc. Prophylactic or therapeutic method for sjogren's syndrome using specific ccr9 receptor inhibitors/antagonists
DK3126330T3 (en) * 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
WO2016057424A1 (en) * 2014-10-06 2016-04-14 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
EP3554541B1 (en) * 2016-12-14 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
US10792360B1 (en) * 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
TWI904146B (zh) * 2020-03-31 2025-11-11 美商卡默森屈有限公司 使用ｃｃｒ９抑制劑及抗ｉｌ-２３阻斷抗體治療發炎性腸道疾病的組成物及方法

Also Published As

Publication number Publication date
AU2020386066A1 (en) 2022-06-09
CN115209896A (zh) 2022-10-18
MX2022006071A (es) 2022-08-02
EP4061365A4 (en) 2023-11-29
BR112022009638A2 (pt) 2022-08-09
KR20220103980A (ko) 2022-07-25
WO2021102302A1 (en) 2021-05-27
JP2023502267A (ja) 2023-01-23
EP4061365A1 (en) 2022-09-28
CA3159127A1 (en) 2021-05-27
US20210154292A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL251136B (en) Combined treatment of c-c receptor inhibitors type 9 (ccr9) and integrin-blocking anti-alha4beta7 antibodies
IL293133A (en) Compositions and methods for treating ccr9-mediated diseases using ccr9 inhibitor and anti-tnf-alpha blocking antibodies
US10792360B1 (en) Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
IL293572A (en) Treatment methods using ilt7 binding proteins
US20240100041A1 (en) Compositions and methods for treating inflammatory bowel disease using ccr9 inhibitor and anti-il-23 blocking antibodies
RU2846370C1 (ru) Композиции и способы лечения воспалительного заболевания кишечника с применением инибитора CCR9 и блокирующих антител против IL-23
RU2823984C2 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРАМИ С-С ХЕМОКИНОВОГО РЕЦЕПТОРА 9 (CCR9) И АНТИТЕЛАМИ, БЛОКИРУЮЩИМИ α4β7-ИНТЕГРИН
IL314334A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
HK1241891B (en) Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease
HK1241891A1 (en) Combination therapy of c-c chemokine receptor-9 (ccr9) inhibitors and anti-alpha4beta7 integrin blocking antibodies for the treatment of inflammatory bowel disease